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pathologic process that results from interruption of blood supply
to the bone. The condition is extremely rare in healthy individuals,
although it occurs usually before the ﬁfth decade. The most
common localization of idiopathic avascular necrosis is the femoral
head, although it affects the knee as well. Pain often occurs only
at an advanced stage of the condition.
Osteoarthritis (OA) conceived as a degenerative consequence of
aging of the joint, with a well-characterized molecular pathophysiol-
ogy, whereas rheumatoid arthritis (RA) is a common, inﬂammatory
polyarthritis. The onset of RA varies from acute to insidious. The
most common site of onset is in the hands and feet. Knee joints
are also commonly affected, although it is not the initial joint.
Peripherially, or centrally released β-endorphin is an important
indicator of pain and inﬂammation. As only a limited number of
papers have been published before on the subject of the analysis
of synovial ﬂuid from hip and knee joint in different arthropathies,
we wish to reply the question whether there is a difference in
between the β-endorphin levels of patients with avascular necrosis,
osetoarthritis and rheumatoid arthritis of the hip and knee. The
role of β-endorphin in alleviation of pain has been well-described,
while there are less data of its function in synovial ﬂuid.
Methods: 87 patients (62 female, 25 male) were involved in our
study with an average age of 62 (±11.27) years. 33 patients
had avascular necrosis of stage IV, V, VI according to Steinberg’s
classiﬁcation (18 hips, 15 knees). 23 patients suffered from OA
(14 hips, 9 knees), whereas stage III-IV RA was diagnosed in 31
patients (12 hips, 19 knees) due to Steinbrocker’s classiﬁcation.
Patients with OA and RA meet the ARA requirements. We mea-
sured the β-endorphin levels of the synovial ﬂuids -harvested from
surgery- with radioimmun assay (RIA).
Results: Our experiments showed elevated level of β-endorphin in
synovial ﬂuid of patients with AVN comparing to OA and RA, how-
ever signiﬁcance was not proven due to a relatively high standard
deviation. Nevertheless β-endorphin level was signiﬁcantly higher
in RA group than among patients with OA (p=0.012). Synovial
β-endorphin level was measured lower in knee comparing to hip
joint. When examining the different joints separately in compliance
with diagnoses, we concluded that the synovial β-endorphin level
from AVN was between the values of OA and RA without signif-
icance, whereas in RA it was signiﬁcantly higher than from OA
irrespectively of the joint (p=0.03 knee, p=0.013 hip).
Conclusions: synovial β-endorphin level in patients with inﬂam-
matory autoimmune diseases (e.g. RA), comparing to the level
measured in degenerative conditions (e.g. OA). We interpret the
higher β-endorphin level in AVN than in OA with the clinically
well-known fact, that AVN is always accompanied by a synovial in-
ﬂammation. The markedly higher β-endorphin level in patients with
RA of the knee contrary to OA conﬁrms the fact that the immune
system has a strong impact on the expression of β-endorphin of
opioid receprors and ligands of peripherial sensorial neurons.
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Purpose: Older patients tend to suffer from osterarthritis of many
joints and osteoporosis. In such cases, several types of fractures
can easily occur. We present a case of sternal fracture after a
subtle trauma in a patient with Kyphosis. 7 days after a very slight
contact injury to her anterior chest, she suddenly experienced
severe pain. To our knowledge, there are no reports of such a
case.
Methods: We present a case of 69-year-old woman with kyposis.
One day, her anterior chest was bumped slightly. She experienced
mild discomfort in the anterior chest. She could, however, spend
daily life without a difﬁculty. 7 days after, her discomfort then
spontaneously transformed into severe pain and she visited a
hospital, but the X-ray examination revealed no rib fractures.
Nevertheless, severe pain persisted, so she visited our hospital 14
days after. On our ﬁrst examination, her anterior chest pain was
very severe. She could not move without help and a great deal of
time was required to change her body position. In our ﬁrst plain X-
ray examination, we could conﬁrm the step off fracture at the body
of the sternum and many old vertebral compression fractures in
her thoracic and lumbar spines. Fracture of the sternum was also
conﬁrmed by computed tomography, and there was no evidence of
tumoral inﬁltration and no obvious abnormality in her mediastinum.
Her bone density was examined using ultrasound, it was only
43% of the mean value for young adults. After conﬁrming chest
X-rays, electrocardiograms, Holter monitoring, echocardiograms,
pulmonary function tests, laboratory tests failed to disclose the
pathology, we made the diagnosis of sternal fracture secondary to
severe osteoporosis and kyphosis.
Results: By conservative treatment with a rib band, 70 days
after the onset, we could see the callus formation around the
fracture and her discomfort became better. But, 3 months after,
her discomfort became worse again and we conﬁrm re-fracture
at the same point. 6 months after, her pain disappeared and we
could conﬁrm callus on the X-ray. It took about a year to conﬁrm
sound bone union.
Conclusions: The sternum and ribs are usually protected from
injury by the elasticity of the costal cartilage. However, these
bones may become progressively ossiﬁed with age such that the
deforming stress due to the thoracic kyphosis may be transmitted
directly to the sternum (Sapherson, 1990). Thoracic kyphosis is
thought to enhance the potential for a sternal insufﬁciency fracture
by creating a deforming stress that exceeds the diminished elastic
resistance of the osteoporotic bone (Cooper, 1988).
Based on the clinical course of our case, sternal insufﬁciency
fracture should have been ruled out ﬁrst. In our case, re-fracture
was also seen at the same point during the treatment course.
So, in the case of the sternal fracture patients with Kyphosis and
osteoporosis, it might be better to take care of the possibility of
re-fracture.
Conclusions: 1) In patients with osteoporosis and spinal com-
pression fractures, sternal fracture must be considered if there are
any complaints of discomfort in the anterior chest. 2) A lateral
view radiograph of the sternum is important for the diagnosis of
sternal fracture. 3) It might be better to take care of the possibility
of re-fracture in the treatment of the sternal fracture patient with
kyphosis and osteopolosis.
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Purpose: The aim of this clinical study was to evaluate the
construct and concurrent validation of chronic pain assessment
methods in dogs diagnosed with osteoarthritis (OA). Different
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behavioural and physiologic pain assessment methods were tested
on OA dogs, and compared to peak vertical force (PVF) measured
on gait analysis. Our hypothesis was that these instruments would
correlate to PVF.
Methods: Twenty-three dogs with lameness were enrolled in the
study. Lameness was conﬁrmed with PVF gait analysis, radio-
graphical and clinical orthopaedic diagnosis. Prior to the ﬁrst eval-
uation, wash out periods were respected for OA pharmaceutical
treatments, nutraceuticals, fatty acid supplement and therapeutic
diets or threats. The clinical trial began with a 30-day period during
which all dogs received a ﬁrst diet. After this period, dogs received
a second diet for a subsequent 60-days period. Owners evaluated
pain using two behavioural rating scales: a standardized multifac-
torial questionnaire (MFQ) and a case-speciﬁc functional assess-
ment (CODI) performed twice per week. Owners scored MFQ at
D0, D30 and D90 with the assistance of a veterinarian. Clinical ex-
amination included measurement of electrodermal activity (EDA),
body weight, and PVF at D0, D30 and D90. A pilot evaluation of
locomotor activity including three parameters [“daily averaged total
intensity” (DATI), “daily peak intensity” (DPI) and “daily proportion
of active period” (DPAP)] was recorded every 2 minutes over the
90-day, using telemetric accelerometer (Actical®/Actiwatch®) on
six dogs. Data analysis and statistics: PVF was corrected to body
weight changes. MFQ and CODI were transformed to be ranged
from 0 (higher pain) to 100 (lower pain).Outcomes of locomotor
activity were averaged for every week of data acquisition. ANOVA
for repeated measures followed by Tukey-Kramer multiple compar-
isons test were applied. Friedman test was used when justiﬁed.
Spearman’s rank correlation coefﬁcient was fulﬁlled to evaluate
construct validation.
Results: MFQ and CODI increased from D0 to D90 (p<0.05).
EDA showed high variability and was unchanged over time. Body
weight was changed over time, and PVF adjusted to body weight
values were at D0: 65.7 (21.0), D30: 67.3 (19.7), and D90: 69.9
(21.3) (p=0.03). For locomotor activity, DATI and DPI were stable
from D0 to D30 but increased from D0 to D90 (p<0.05).
CODI and MFQ were positively correlated (rho = 0.45, p<0.001).
CODI was positively correlated to the DATI of locomotor activity
over the 12 weeks of recording (rho = 0.42, p<0.001). PFV
adjusted to body weight trended to correlate to DATI from D0 to
D30 (p=0.11), and descriptive analysis demonstrated at D90 that
PVF increase was also associated to increase in DATI, DPI and
DPAP.
Conclusions: CODI, the behavioural pain rating scale developed
for each speciﬁc dog and owner, was indicator of level of activity
in dogs, but was not correlated to orthopaedic disability per se.
Gait analysis was indicator of orthopaedic ability and endurance
to be active. CODI and gait analysis had good construct validation
and were complementary evaluations to evaluate chronic pain
caused by OA in dogs. Locomotor activity looks as an objective
behavioural evaluation and a potent complement to PVF gait
analysis.
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Purpose: Glucosamine sulphate (GS) and chondroitin sulphate
(CS) are symptomatic slow-acting drugs for osteoarthritis (OA)
widely used in clinic. However, their mechanism of action re-
mains poorly characterized. Since the variability in the treatment
efﬁcacy of these compounds is in accordance with the patholog-
ical OA degree (severe-moderate-mild), we decided to carry out
our experiments in normal chondrocyte cultures stimulated with
Interleukin-β. IL-1β is an arthritic mediator with the capacity to
drive the key pathways typically associated with the pathogen-
esis of OA. The aim of this work is to explore the utility of a
pharmacoproteomic approach for the identiﬁcation of mechanisms
and speciﬁc molecules involved in the pharmacological effect of
glucosamine sulphate and chondroitin sulphate.
Methods: Chondrocytes obtained from 3 healthy donors were
treated with GS 10mM and/or CS 200μg/mL, and then stimulated
with IL-1β 10ng/mL. Whole cell proteins were isolated 24 hours
after cellular stimulation and resolved by two-dimensional elec-
trophoresis. The gels were stained with SYPRORuby and digitized
using a CCD camera. The image analysis was performed using the
PDQuest 7.3.1 computer software. Differentially abundant proteins
were identiﬁed by matrix-assisted laser desorption/ionization-time
of ﬂight mass spectrometry. Visualization of modulated biological
pathways was carried out using Pathway Studio software. Real-
time and western blot analyses were performed to validate our
results.
Results: We examined a mean of 500 protein spots that were
present in each gel. Both qualitative and quantitative changes in
protein expression patterns between controls and treated cells
were studied. We identiﬁed 39 protein spots that were modulated
by GS treatment, 35 by CS treatment and 48 by GS+CS treatment
compared to the control. Database search showed that most of
these proteins are involved in protein folding (PDIA1, PDIA3),
stress response (HSP7C, HSPB1, ANXA2), cellular metabolism
(AK1C2, PGK1, KPYM), protein targeting (GRP78) and oxidative
stress (SOD2, PRDX1). Considering that oxidative stress balance
has been reported to play an essential role in osteoarthritis,
we found SOD2 upregulated by IL-1β and downregulated by
GS and CS treatment, both at transcription and protein levels.
Biological signiﬁcance of these data included the drug-dependent
decrease of superoxide dismutase activity that we detected in
cartilage cells, and also the reduction in ROS generation. On
the other hand, GRP78, a protein previously characterized by its
anti-inﬂammatory properties and recently proposed as a potential
new biologic therapy for RA, resulted increased by GS, alone and
in combined administration. This is the ﬁrst study carried out in
chondrocytes that conﬁrms the GS effect as positive modulator of
Grp78 expression and points to a speciﬁc mechanism of action of
this compound for its putative anti-inﬂammatory effect.
Conclusions: The present study uses an in vitro model of in-
ﬂammation (using IL-1β) to describe the effect of GS and CS on
cartilage cells. We have identiﬁed several novel molecular targets
of these compounds, such as SOD2 and GRP78, which may
